Product Description
The research-grade biosimilar is a human IgG2 monoclonal antibody that is directed against proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a serine protease that binds to LDL receptors on the hepatocyte cell surface and promotes the lysosome-mediated degradation of these receptors. This results in decreased uptake and clearance of LDL-C (bad cholesterol) by the receptors. The monoclonal antibody binds to PCSK9 and prevents interaction with the LDL receptor. This promotes the recycling of the internalized LDL receptor to the hepatocyte cell surface and increased removal of LDL-C from the blood. The original drug received approval from the FDA to treat homozygous and heterozygous familial cholesterolemia. The drug has also been approved to treat patients with high cholesterol, whose LDL-C was not controlled by the statin treatment.
Biovision | A2168 | Anti-PCSK9 (Evolocumab), Human IgG2 Antibody DataSheet
Antibody Target: PCSK9
Target Alternative Name: AMG-145, AMG145, NN7415, FH3, PC9, FHCL3, NARC1, LDLCQ1, NARC-1, HCHOLA3
Tag Line: The biosimilar is a human monoclonal antibody that targets PCSK9 and inhibits the binding with LDL receptors on the hepatocyte cell surface and promotes the clearance of LDL-C from the blood
Category: Biosimilars
Host: Recombinant
Isotype: IgG2, lambda
Species Reactivities: Human
Immunogen Sequence: Human PCSK9
Accession #: DB09303
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE